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Abstract
Purpose To examine whether age-related reference ranges for “normal” prostate-specific antigen (PSA) change (determined 
in men without prostate cancer) can be used to identify men at high risk of having prostate cancer.
Methods Subjects were men aged 50–69 years with PSA < 10 ng/mL from the UK-based Prostate Testing for cancer and 
Treatment (ProtecT) study. Men with prostate cancer were categorized as high or low risk of progression (Low risk: Gleason 
score ≤ 6 and stage T1–T2a; High risk: Gleason score 7–10 or stage T2C). Men without prostate cancer were those with no 
histological confirmation of prostate cancer. Previously developed longitudinal reference ranges for normal age-related PSA 
change were used to calculate an age-specific PSA threshold. We compared the ability of our age-specific PSA threshold to 
discriminate between high- and no/low-risk prostate cancer with that of two existing thresholds: (i) threshold of PSA = 3 ng/
ml for all ages; (ii) National Institute of Clinical Excellence (NICE) guidelines dependent on age-group thresholds (age 
50–59: PSA = 3 ng/mL; age 60–70: PSA = 4 ng/mL; age ≥ 70: PSA = 5 ng/mL).
Results We included 823 men with high-risk prostate cancer and 80,721 men with no/low-risk prostate cancer. A threshold 
of PSA = 3 ng/ml for all ages identified more high-risk prostate cancers, recommending biopsy in 9.8% of men, of which 
10.3% (n = 823) had high-risk prostate cancer. Using the NICE guidelines as the threshold for biopsy, 6.9% men were recom-
mended for biopsy, of which 11.9% (n = 668) had high-risk prostate cancer. Using the new age-specific threshold for biopsy, 
2.3% men were recommended for biopsy, of which 15.2% (n = 290) had high-risk prostate cancer. The age-specific threshold 
identified fewer high-risk prostate cancers, but fewer men received unnecessary biopsy.
Conclusion There is no benefit to using reference ranges for “normal” PSA that change with age nor the age-specific thresh-
olds suggested by the NICE guidelines. While the age-varying thresholds are more discriminatory, too many high-risk 
cancers are missed.
Keywords Prostate cancer · Prostate-specific antigen testing · Biopsy · Age · Reference ranges
Introduction
Prostate-specific antigen (PSA) testing, followed by biopsy 
if the PSA level is raised (typically ≥ PSA 3–4 ng/mL), is a 
widely accepted screening method for prostate cancer [1]. 
However, most screen-detected prostate cancers have low 
risk of progression, with potential harm caused by unneces-
sary treatment [2, 3].
Despite widespread use of PSA testing, men with raised 
PSA may have no evidence of prostate cancer at biopsy, 
while not all men with prostate cancer have raised PSA [4]. 
PSA levels increase with age, and the natural variability in 
PSA level (both within men over time, and between men) 
is likely to be greater in older men [5], thus obscuring dis-
ease-related changes. Current age-related PSA thresholds 
are based on cross-sectional data and hence do not attempt 
to distinguish these different sources of variability, nor to 
describe serial changes in PSA level for aging individuals.
The aim of the current study was to examine whether 
age-related reference ranges for “normal” PSA change 
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(determined in men without prostate cancer) can be used 
to identify men at high risk of having prostate cancer. We 
hypothesize that a higher threshold will be identified for 
older men, which will identify clinically relevant prostate 
cancers at high risk of progression while saving some men 
from unnecessary biopsy.
Methods
The study is nested within a multicenter randomized con-
trolled trial of treatments for localized prostate cancer: 
the Prostate Testing for cancer and Treatment (ProtecT) 
study [6]. Between 2001 and 2009, over 100,000 men aged 
50–69 years attended a ‘prostate check clinic’ where they 
were offered a PSA test. Those with raised levels (≥ 3 ng/
mL) were offered diagnostic biopsy. Tumors were histo-
logically confirmed, clinically staged (“localized”: T1–T2; 
“locally advanced”: T3–T4) [7], and Gleason graded.
Men were included in the current study if they had 
PSA < 10 ng/mL, as PSA above this level would normally 
warrant further investigation.
Men with prostate cancer were categorized as low risk 
of progression if their Gleason score was six or less and 
stage T1–T2a, and as high risk of progression if their Glea-
son score was seven to ten or stage T2b–T4, adapted from 
the NICE guidelines [9]. For 137 men who had Gleason 
score ≤ 6 but no stage, and 23 men who had stage T1–T2a 
but no Gleason score, a low risk of progression was assumed.
Men without prostate cancer were defined as those with 
no histological confirmation of prostate cancer, i.e., (i) 
PSA < 3 ng/mL; (ii) PSA ≥ 3 ng/mL and a negative biopsy 
result.
Longitudinal reference ranges for normal PSA change 
with age were developed previously using data from the 
Krimpen longitudinal community-based study [8], specifi-
cally serial PSA measurements from men aged 50–78 years 
who did not have prostate cancer (n = 1,462).
An upper bound for age-specific PSA level, above which 
the fastest increasing 2.5% of men lie, can be estimated using 
the PSA level for each age as described by Krimpen (Fig. 1). 
If PSA falls above this reference range, then it is implied 
that the patient’s PSA is above what would be expected due 
to normal aging. For example, at age 50, a man would be 
recommended for biopsy if his PSA ≥ 2.8 ng/mL. At age 
55 years, a man would be recommended for biopsy if his 
PSA ≥ 3.8 ng/mL, and, at 65 years, if his PSA ≥ 7.6 ng/mL.
We compared the ability of the new age-specific threshold 
to discriminate between high-risk and no/low-risk prostate 
cancer with that of two existing thresholds: (i) threshold of 
PSA = 3 ng/ml for all ages; (ii) National Institute for Health 
and Care Excellence (NICE) guidelines depending on age 
group (age 50–59: PSA = 3 ng/mL; age 60–70: PSA = 4 ng/
mL; age ≥ 70: PSA = 5 ng/mL) [9].
For each threshold, we calculated the number of (i) men 
with high-risk prostate cancer and PSA above the threshold 
(i.e., true positive (TP)), (ii) men with no or low-risk pros-
tate cancer and PSA below the threshold (i.e., true negative 
(TN)), (iii) men with no or low-risk prostate cancer and PSA 
above the threshold (i.e., false positive (FP)), and (iv) men 
with high-risk prostate cancer and PSA below the thresh-
old (i.e., false negative (FN)). Analyses are stratified by age 
group.
We additionally calculated the diagnostic likelihood ratio 
(LR) as sensitivity/(1-specificity), where sensitivity is the 
proportion of high-risk prostate cancers correctly identified 
as such (= TP/(TP + FN)) and specificity is the proportion of 
no or low-risk prostate cancers correctly identified as such 
(TN/(FP + TN)). A higher value of the LR indicates that a 
test is better able to discriminate between men with high-
risk prostate cancer and those with no or low-risk prostate 
cancer.
Analyses were carried out in Stata 14 (StataCorp, 2014. 
College Station, TX).
Results
There were 81,553 men aged ≥ 50 years with at least one 
PSA result and PSA ≤ 10 ng/mL. 9 men were dropped from 
analysis as their clinical information was missing. Of the 
remaining 81,544 men, 2,556 (3.1%) men had prostate can-
cer. The current analysis includes 823 men with clinically 
relevant prostate cancer at high risk of progression and 
80,721 men with no (n = 78,988) or low risk of progression 
(n = 1,733) prostate cancer.
There were no substantial differences in baseline charac-
teristics between men with high-risk prostate cancer and no/
low-risk prostate cancer other than mean age (62.4 years vs. 
59.3 years, p ≤ 0.001) and mean PSA level (5.5 vs. 1.3 ng/
mL, p ≤ 0.001) (Table S1).
Using a threshold of PSA = 3 ng/ml for all ages as the 
threshold for biopsy resulted in 8,015 men (9.8%) being rec-
ommended for biopsy, of which 823 (10.3%) had high-risk 
prostate cancer. THE LR was 11.2 (Table 1; Fig. 1).
Using the NICE guidelines based on age group as the 
threshold for biopsy resulted in 5,626 (6.9%) men being rec-
ommended for biopsy, of which 668 (11.9%) had high-risk 
prostate cancer. Within men who had no or low-risk pros-
tate cancer 2,235 men were saved unnecessary biopsy when 
using the NICE guidelines based on age group compared 
with a threshold of PSA = 3 ng/mL for all ages at the cost of 
not identifying 155 men with high-risk prostate cancer. The 
LR was 13.3 (Table 1; Fig. 1).
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Using the new age-specific threshold for biopsy resulted 
in 1,909 (2.3%) men being recommended for biopsy, of 
which 290 (15.2%) had high-risk prostate cancer. Within 
men who had no or low-risk prostate cancer 5,579 men were 
saved unnecessary biopsy when using the new age-specific 
threshold compared with a threshold of PSA = 3 ng/mL for 
all ages at the cost of not identifying 533 men with high-risk 
prostate cancer. The LR was 17.6 (Table 1; Fig. 1).
Discussion
In UK men aged 50–69 years, using reference ranges for 
“normal” PSA change with age or the age group-specific 
thresholds suggested by the NICE guidelines resulted in 
fewer unnecessary biopsies but at the cost of more missed 
prostate cancers. While the threshold of PSA = 3 ng/mL 
for all ages identified more prostate cancers at high risk of 
progression than either of the other two thresholds, result-
ing in fewer missed prostate cancers, more men received 
an unnecessary prostate biopsy. The diagnostic likelihood 
ratios suggest that the thresholds that incorporate age do 
give a more discriminatory test. However, the number 
of high-risk prostate cancers that are missed by the age-
specific threshold test and the thresholds suggested by the 
NICE guidelines means that these tests are unacceptable 
in practice.
Other age-adjusted PSA thresholds for biopsy have been 
suggested [10], although these have been for age groups and 
based on cross-sectional data. Tests of these age-adjusted 
cut-offs showed inconclusive results, although age-adjusted 
thresholds for PSA were recommended in the majority of 
cases. This method has not become widely accepted in clini-
cal use or screening programs among concerns about miss-
ing a high proportion of clinically significant cancers in older 
men while augmenting the rate of unnecessary biopsies in 
younger men. Results from the Tyrol Prostate Cancer Early 
Detection Program found that age-adjusted PSA thresholds 
using PSA and free PSA levels achieved a similar sensitivity 
while simultaneously reducing the number of biopsies [11]. 
Results from another study using the same data as the cur-
rent study found that an age- and BMI-adjusted PSA model 
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Fig. 1  Graph showing PSA level (ng/mL) plotted against age (both 
measured at the prostate check clinic).The lines depict the three 
thresholds of PSA which may trigger further investigations (i) a 
threshold of PSA = 3 ng/mL for all ages (--- line); (ii) NICE thresh-
olds (age 50–59: PSA = 3  ng/mL; age 60–70: PSA = 4  ng/mL; 
age ≥ 70: PSA = 5  ng/mL) (-- -- -- line); (iii) age-specific thresh-
old developed in the current study above which the fastest increas-
ing 2.5% of men lie (solid line). The performance of the threshold 
depends on the age distribution of the data so the graphs have been 
stratified by age group. A random sample of men were plotted to 
improve readability. X indicates a man diagnosed with clinically 
significant prostate cancer (1 in 200 men plotted, n = 406). A dot 
indicates a man not diagnosed with prostate cancer or with prostate 
cancer at low risk of progression (1 in 100 men, n = 813). An upper 
bound for age-specific PSA level, above which the fastest increas-
ing 2.5% of men lie, can be estimated using the PSA level for each 
age as described by the Krimpen study [8]. The plotted points, where 
age (years):PSA(ng/mL), are: 50:2.8, 51:3.0, 52:3.2, 53:3.4, 54:3.6, 
55:3.8, 56:4, 57:4.2, 58:4.6, 59:4.9, 60:5.2, 61:5.6, 62:6.1, 63:6.5, 
64:7, 65:7.6, 66:8.3, 67:9, 68:9.8, 69:10.4, 70:11.3
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was no more clinically useful for detecting prostate cancer 
than the current NICE guidelines [12].
Men in the ProtecT study with a PSA < 3 ng/mL were not 
biopsied and may have had undiagnosed prostate cancer, 
resulting in calculated sensitivities that are not reflective of 
the true sensitivities. Consequently, while the sensitivity 
and specificity for the PSA thresholds in this study can be 
directly compared, they should not be compared with the 
true sensitivity and specificity of PSA testing as published 
by previous studies, and we do not refer to them as sensitiv-
ity or specificity throughout this article to avoid confusion. 
The new age-specific threshold would recommend that men 
aged 50 years use a threshold of PSA = 2.8 ng/mL. These 
men were not biopsied in ProtecT and so may have had undi-
agnosed prostate cancer.
The only threshold that would lead to men with a 
PSA < 3  ng/mL being biopsied is the new age-specific 
threshold, where the threshold is less than 3 ng/mL for 
younger men (men aged 50 years would be biopsied if their 
PSA was 2.8 ng/mL). By the time the men are 51 years, the 
threshold is 3 ng/mL.
Conclusion
In this cohort of UK men aged 50–69 years, there is no evi-
dence of benefit from using reference ranges for “normal” 
PSA change with age nor the age-specific thresholds sug-
gested by the NICE guidelines (age 50–59: PSA = 3 ng/mL; 
age 60–70: PSA = 4 ng/mL; age ≥ 70: PSA = 5 ng/mL). A 
threshold of PSA = 3 ng/mL for all ages identified more clin-
ically relevant prostate cancers at high risk of progression 
than either of the other two thresholds, resulting in fewer 
missed prostate cancers, but at the cost of more men receiv-
ing an unnecessary prostate biopsy. While the age-varying 
thresholds are more discriminatory, too many high-risk can-
cers are missed.
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